HR‐positive, HER2‐positive breast cancer (triple‐positive breast cancer [TPBC]) tends to respond clinically to neoadjuvant targeted therapy more often than HR‐negative, HER2‐positive breast cancer due to crosstalk between HER2 and hormone receptor (HR) signaling pathways. This evidence concerns the gene NR4A1 and breast cancer.